Barrand M A, Heppell-Parton A C, Wright K A, Rabbitts P H, Twentyman P R
MRC Clinical Oncology and Radiotherapeutics Unit, MRC Centre, Cambridge, England.
J Natl Cancer Inst. 1994 Jan 19;86(2):110-7. doi: 10.1093/jnci/86.2.110.
A 190k (190-kilodalton) membrane protein has been identified in several multidrug-resistant (MDR) cell lines that show decreased drug accumulation without expression of P-glycoprotein. It is not clear whether this 190k protein is involved directly in drug efflux. Recently, a gene for a putative transporter protein, MRP (multidrug resistance-associated protein) has been sequenced and localized to chromosome 16. The protein encoded by this gene contains a 7-amino-acid sequence present in the synthetic peptide used to generate the antiserum recognizing the 190k protein.
The study was undertaken to clarify the relationship of the 190k protein to MRP gene expression in non-P-glycoprotein-containing MDR cells of the large-cell and adenocarcinoma lung cancer lines, COR-L23 and MOR.
Expression of the 190k protein was determined by Western blot analysis and that of the MRP gene by polymerase chain reaction amplification of complementary DNA reverse transcribed from RNA. Abnormalities of chromosome 16 were investigated in chromosome spreads by fluorescence in situ hybridization.
The amount of detectable 190k protein is closely associated with degree of drug resistance. Cell lines surviving in higher drug concentrations have greater amounts of protein, and revertant lines grown without drug for up to 28 weeks show reduced expression of the protein together with enhanced drug sensitivity. The 190k protein appears to be one of the major proteins differentially expressed in membranes of drug-resistant cells. The amount of MRP messenger RNA correlates closely with that of the 190k protein. The MDR cells contain amplified chromosome 16 material with many double minutes in the large-cell lung tumor lines and an enlarged chromosome 16 in the adenocarcinoma lines.
The 190k protein detected immunologically is likely to be the protein, encoded by the MRP gene, which becomes overexpressed in these cells as a consequence of chromosomal amplification and fragmentation.
Though associated with drug resistance, enhanced drug efflux, and decreased drug accumulation in cell lines, the role of this protein in clinical resistance has yet to be determined.
在几种多药耐药(MDR)细胞系中已鉴定出一种190k(190千道尔顿)膜蛋白,这些细胞系显示药物蓄积减少且无P - 糖蛋白表达。尚不清楚这种190k蛋白是否直接参与药物外排。最近,一种假定的转运蛋白基因MRP(多药耐药相关蛋白)已被测序并定位到16号染色体。该基因编码的蛋白含有一段7个氨基酸的序列,该序列存在于用于制备识别190k蛋白的抗血清的合成肽中。
本研究旨在阐明在大细胞肺癌系COR - L23和腺癌系MOR的不含P - 糖蛋白的MDR细胞中,190k蛋白与MRP基因表达之间的关系。
通过蛋白质印迹分析确定190k蛋白的表达,通过对从RNA反转录的互补DNA进行聚合酶链反应扩增来确定MRP基因的表达。通过荧光原位杂交在染色体铺片中研究16号染色体的异常情况。
可检测到的190k蛋白的量与耐药程度密切相关。在较高药物浓度下存活的细胞系具有更多的该蛋白,而在无药物条件下生长长达28周的回复株系显示该蛋白表达降低以及药物敏感性增强。190k蛋白似乎是耐药细胞膜中差异表达的主要蛋白之一。MRP信使RNA的量与190k蛋白的量密切相关。MDR细胞在大细胞肺癌系中含有扩增的16号染色体物质且有许多双微体,在腺癌系中有一条增大的16号染色体。
通过免疫检测到的190k蛋白可能是由MRP基因编码的蛋白,由于染色体扩增和断裂,该蛋白在这些细胞中过度表达。
尽管该蛋白与细胞系中的耐药性、增强的药物外排和药物蓄积减少有关,但其在临床耐药中的作用尚未确定。